ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0025741 | An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. | O methyl DOPA|methyldopa (levorotatory)|Methyldopa-containing product|AMD|alpha-Methyldopa|alpha-methyldopa|L-Tyrosine, 3-hydroxy-alpha-methyl-|L-alpha-Methyldopa|Methyldopa (substance)|Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine|(S)-(-)-alpha-Methyldopa|alpha-Methyl dopa|alpha-methyl-L-dopa|Alphamethyldopa|α-methyl-L-dopa|Product containing methyldopa (medicinal product)|METHYLDOPA|3-Hydroxy-alpha-methyl-L-tyrosine|L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid|alpha-Methyl-L-Dopa|metildopa|alpha methyldopa|alpha Methyldopa|methyldopa|alpha Methyl L Dopa|Methyldopa|alphamethyldopa|Methyl dopa|α-Methyl dopa|L-Methyl Dopa|Alpha medopa | methyldopa |
C1267092 | Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed) | muscle smooth|involuntary muscle|Smooth muscle (tissue) (body structure)|Involuntary Muscles|Muscle, Smooth|muscles smooth|nonstriated muscle|SMOOTH MUSCLE TISSUE|MUSCLE, SMOOTH|Smooth muscle (tissue)|Smooth Muscle Tissue|Smooth muscle tissue|Smooth Muscles|Involuntary Muscle|Muscles, Involuntary|Smooth muscle|Smooth muscle (organ) structure (body structure)|Smooth muscle (organ)|muscle involuntary|Muscle, Involuntary|smooth muscle tissue|smooth tissue muscle|smooth muscles|involuntary muscles|Smooth Muscle|Non-striated muscle|Portion of smooth muscle tissue|Smooth muscle, NOS|smooth muscle|Textus muscularis nonstriatus|Involuntary muscle|Muscles, Smooth|Smooth muscle (organ) structure|SMOOTH MUSCLE | Smooth muscle (tissue) |
C1565434 | A family of non-receptor, PROLINE-rich protein-tyrosine kinases. | Focal Adhesion Kinase|Focal Adhesion Protein Tyrosine Kinases|Focal Adhesion Protein Tyrosine Kinase Family|Focal Adhesion Protein-Tyrosine Kinase Family|Focal adhesion kinase|Focal Adhesion Protein-Tyrosine Kinase|Focal Adhesion Protein-Tyrosine Kinases | Focal Adhesion Protein-Tyrosine Kinases |
C0005863 | Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. | Immunoblottings, Western|Western immunoblotting|Western Immunoblotting|Western Immunoblottings|Western Blottings|protein blotting|Blottings, Western|Western Blot|Immunoblotting, Western|western blotting|WESTERN BLOT|Western blotting|blotting western|Western Blotting|Blotting, Western | Western Blotting |
C0887870 | Small region on the surface of a cell that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. [ISBN:0124325653, ISBN:0815316208] | Adherens Junctions, Cell-Matrix|focal contact|Adhesion, Focal|Focal adhesions|Contacts, Focal|Junction, Cell-Matrix Adherens|Focal Contacts|Cell-Matrix Adherens Junctions|Cell-to-Extracellular Matrix Junction|Adherens Junction, Cell-Matrix|Contact, Focal|Focal contact|Cell-to-Matrix Junction|Cell-to-extracellular matrix junction|Adhesions, Focal|Focal Adhesion|Cell to matrix adherens junction|focal adhesion|Focal adhesion plaque|Plaques, Adhesion|Focal Adhesions|Plaque, Adhesion|Junctions, Cell-Matrix Adherens|Focal Contact|Cell Matrix Adherens Junctions|Adhesion Plaque|Cell-Matrix Adherens Junction|Adhesion Plaques | Focal Adhesions |
C0086714 | null | noramidopyrine methanesulfonate|Noramidopyrine Methanesulfonate|Noramidopyrine methanesulfonate | Noramidopyrine Methanesulfonate |
C0086714 | null | noramidopyrine methanesulfonate|Noramidopyrine Methanesulfonate|Noramidopyrine methanesulfonate | Noramidopyrine Methanesulfonate |
C0044602 | A phosphatidylinositol 3-kinase that catalyzes the conversion of 1-phosphatidylinositol into 1-phosphatidylinositol 3-phosphate. | EC 2.7.1.153|1-phosphatidylinositol 3-kinase|3 pi kinase|pi 3 kinase|Phosphatidylinositol 3 Kinase|1 Phosphatidylinositol 3 Kinase|Phosphoinositide 3 Kinase|Phosphatidylinositide 3-Kinase|PI3 kinase|Phosphatidylinositol-3-Kinase|pi3-kinase|phosphatidylinositol 3-kinase|1-Phosphatidylinositol 3-Kinase|1-phosphatidylinositol 3-kinase (substance)|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase|Phosphatidylinositol 3-Kinase|PI3 Kinase|Phosphatidylinositol 3-kinase|PI3k|PI 3 Kinase|pi3 kinase|Kinase, Phosphoinositide 3|PI3K|3 kinases pi|PI3-Kinase|Type I Phosphatidylinositol Kinase|phosphatidylinositol-3 kinase|Type III Phosphoinositide 3-Kinase|PI3-kinase|phosphatidylinositol 3 kinase | 1-Phosphatidylinositol 3-Kinase |
C0812387 | null | feels cold|cold feelings|feel cold|cold to touch|cold feels|Coldness|coldness|CHILLINESS|cold feel|cold touch|COLDNESS GENERAL | Feels cold |
C0812387 | null | feels cold|cold feelings|feel cold|cold to touch|cold feels|Coldness|coldness|CHILLINESS|cold feel|cold touch|COLDNESS GENERAL | Feels cold |
C0110610 | A CCN protein family member that regulates a variety of extracellular functions including CELL ADHESION; CELL MIGRATION; and EXTRACELLULAR MATRIX synthesis. It is found in hypertrophic CHONDROCYTES where it may play a role in CHONDROGENESIS and endochondral ossification. | Connective Tissue Growth Factor|Hypertrophic Chondrocyte Specific Protein 24|CCN2 Protein|Insulin-Like Growth Factor Binding Protein 8|fisp12 protein|Connective tissue growth factor|IGF-Binding Protein-Related Protein-2|IGFBP-rP2|CTGF|Insulin-like growth factor binding protein 8|Insulin Like Growth Factor Binding Protein 8|connective tissue growth factor|IGFBP-8|IGF Binding Protein Related Protein 2|IGF-BP 8 - Insulin-like growth factor binding protein 8|ctgf|Connective tissue growth factor (substance)|Hypertrophic Chondrocyte-Specific Protein 24 | connective tissue growth factor |
C0300500 | null | receptor, adhesion|adhesion receptors | adhesion receptor |
C0017661 | A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. | NEPHROPATHY, IGA|Berger's disease|focal glomerulonephritis|IgA Nephropathy|Nephropathy 1, Iga|BERGER DISEASE|Iga Nephropathy 1|IGA Nephropathy|Immunoglobulin A Nephropathy|Berger's Disease|disease berger|Berger Disease|IGAN|Nephropathy, IGA|Glomerulonephritides, IGA|IgA glomerulonephritis|Mesangial IgA/IgG disease|IGA Type Nephritis|NEPHRITIS, IgA TYPE|Nephropathy, Immunoglobulin A|Immunoglobulin A nephropathy (disorder)|segmental glomerulonephritis|IGA NEPHROPATHY|IgA nephropathy|Focal Glomerulonephritis|Bergers Disease|berger disease|IgAN - IgA nephropathy|nephropathy iga|Immunoglobulin A nephropathy|glomerulonephritis iga|IgA/IgG nephropathy of Berger|Bergers disease|Glomerulonephritis, IGA|iga glomerulonephritis|berger's disease|IDIOPATHIC FOCAL NEPHRITIS WITH MESANGIAL DEPOSITS OF IGA|glomerulonephritis focal|GLOMERULONEPHRITIS FOCAL|iga nephropathy|Nephritis, IGA Type|IGA Glomerulonephritis|bergers disease | IGA Glomerulonephritis |
C0194073 | Removal of tissue from the kidney, for microscopic examination. | renal biopsy|Biopsy of Kidney|biopsies renal|Kidney biopsy|Renal biopsy|Kidney Biopsy|kidney biopsy|biopsy kidney|biopsy renal|biopsy of kidney|biopsy kidneys|Renal biopsy, NOS|Kidney biopsy, NOS|Renal Biopsy|Kidney biopsy (procedure)|biopsies kidney | Kidney biopsy |
C0015689 | A group of unsaturated fatty acids occurring mainly in fish oils, with three double bonds at particular positions in the hydrocarbon chain. | Omega-3 fatty acids|omega-3-fatty acids|PUFA, n3|Fatty Acid, n3|Omega 3 Fatty Acids|omega 3 fatty acid|fatty acid omega 3|omega-3 polyunsaturated fatty acid|n3 PUFA|Omega-3 Polyunsaturated Fatty Acid|n 3 Polyunsaturated Fatty Acid|n-3 Oils|ω-3 fatty acids|Omega-3 polyunsaturated fatty acids|Omega-3 acid|Omega-3 acid triglycerides|Omega 3 fatty acid|n-3 Polyunsaturated Fatty Acid|omega-3-Fatty Acids|Omega-3 polyunsaturates|n 3 Oils|omega-3 PUFA|Omega 3 fatty acids|n-3 Fatty Acids|Fatty Acids, Omega-3|OMEGA-3 FATTY ACIDS|N-3 fatty acid|n-3 PUFA|PUFA, n-3|Omega-3 Fatty Acid|n3 Polyunsaturated Fatty Acid|omega-3 fatty acid|n-3 Fatty Acid|OMEGA-3 POLYUNSATURATED FATTY ACIDS|n 3 Fatty Acids|n3 Oils|n-3 fatty acids|omega 3|n3 Fatty Acid|omega-3|Omega 3 Fatty Acid|Omega-3 PUFA|Omega-3 Fatty Acids|N-3 fatty acid (substance)|n-3 fatty acid|Omega-3|OMEGA-3 ACID|Omega-3 phospholipids|n 3 PUFA|Omega-3 fatty acid|omega 3 fatty acids|omega-3 fatty acids | omega-3 fatty acids |
C0024015 | City in California. | los angeles|angeles los | Los Angeles |
C0024015 | City in California. | los angeles|angeles los | Los Angeles |
C0015689 | A group of unsaturated fatty acids occurring mainly in fish oils, with three double bonds at particular positions in the hydrocarbon chain. | Omega-3 fatty acids|omega-3-fatty acids|PUFA, n3|Fatty Acid, n3|Omega 3 Fatty Acids|omega 3 fatty acid|fatty acid omega 3|omega-3 polyunsaturated fatty acid|n3 PUFA|Omega-3 Polyunsaturated Fatty Acid|n 3 Polyunsaturated Fatty Acid|n-3 Oils|ω-3 fatty acids|Omega-3 polyunsaturated fatty acids|Omega-3 acid|Omega-3 acid triglycerides|Omega 3 fatty acid|n-3 Polyunsaturated Fatty Acid|omega-3-Fatty Acids|Omega-3 polyunsaturates|n 3 Oils|omega-3 PUFA|Omega 3 fatty acids|n-3 Fatty Acids|Fatty Acids, Omega-3|OMEGA-3 FATTY ACIDS|N-3 fatty acid|n-3 PUFA|PUFA, n-3|Omega-3 Fatty Acid|n3 Polyunsaturated Fatty Acid|omega-3 fatty acid|n-3 Fatty Acid|OMEGA-3 POLYUNSATURATED FATTY ACIDS|n 3 Fatty Acids|n3 Oils|n-3 fatty acids|omega 3|n3 Fatty Acid|omega-3|Omega 3 Fatty Acid|Omega-3 PUFA|Omega-3 Fatty Acids|N-3 fatty acid (substance)|n-3 fatty acid|Omega-3|OMEGA-3 ACID|Omega-3 phospholipids|n 3 PUFA|Omega-3 fatty acid|omega 3 fatty acids|omega-3 fatty acids | omega-3 fatty acids |
C0232804 | physiological activity and functions of the kidneys as a whole or of any of its parts, including filtering the blood for the secretion of urine. | functions kidneys|functions kidney|function renal|function kidney|renal function|function kidneys|functions renal|Renal function, NOS|Renal function (observable entity)|Renal function|kidney function | Renal function |
C1159690 | The directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:ai] | sodium transport | sodium ion transport |
C0077932 | null | urotensin II | urotensin II |
C0042036 | Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA. | Piss|Urine (substance)|Pee|URINE|Urine|urine|Urinary System, Urine | Urine |
C0222607 | null | collecting duct|Structure of collecting duct of nipple (body structure)|Collecting duct|Structure of collecting duct of nipple|collecting ducts | Breast collecting duct |
C1283597 | null | Glomerular arteriole (body structure)|Glomerular arteriole | Glomerular arteriole |
C1305694 | Organ component, each instance of which is an inneer layer or region of some organ. | Medulla|medulla | Medulla |
C0151746 | An abnormal functionality of the kidney. [HPO:probinson] | Abnormal kidney function|Renal function, abnormal|KIDNEY DYSFUNCTION|abnormal renal function|DYSFUNCTION KIDNEY|dysfunctions kidney|Abnormality of renal physiology|RENAL FUNCTION ABNORMAL|Abnormal renal physiology|Abnormal renal function (finding)|dysfunction kidney|Kidney function issue|abnormal kidney function|kidney dysfunction|KIDNEY FUNCTION ABNORMAL|FUNCTION KIDNEY ABNORMAL|Renal functional abnormality|Abnormal renal function | Abnormal renal function |
C0155626 | Necrosis of the myocardium, as a result of interruption of the blood supply to the area. It is characterized by a severe and rapid onset of symptoms that may include chest pain, often radiating to the left arm and left side of the neck, dyspnea, sweating, and palpitations. | acute myocardial infarction (MI)|Acute Myocardial Infarction|MYOCARDIAL INFARCTION ACUTE|AMI|Acute myocardial infarction (disorder)|Acute myocardial infarction NOS|AMI - Acute myocardial infarction|Acute myocardial infarction, NOS|Acute myocardial infarction|Acute myocardial infarction, unspecified site|acute mi|MI, ACUTE|ami|Acute myocardial infarction of unspecified site, episode of care unspecified|acute myocardial infarction|MYOCARDIUM, INFARCTION, ACUTE | Acute myocardial infarction |
C0948089 | Signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction. | Acute coronary syndrome (disorder)|acute coronary syndrome|Syndromes, Acute Coronary|Coronary Syndrome, Acute|ACS - Acute coronary syndrome|Syndrome, Acute Coronary|Acute Coronary Syndromes|syndrome acute coronary|Acute coronary syndrome|Acute Coronary Syndrome|Coronary Syndromes, Acute|acute coronary syndromes | Acute Coronary Syndrome |
C0041199 | One of the minor protein components of skeletal and cardiac muscles. It functions as the calcium-binding component in a complex with BETA-TROPOMYOSIN; ACTIN; and MYOSIN and confers calcium sensitivity to the cross-linked actin and myosin filaments. Troponin itself is a complex of three regulatory proteins (TROPONIN C; TROPONIN I; and TROPONIN T). | Troponin|Troponin Complex|Troponin (substance)|Troponin, NOS|troponins|Troponins|Troponin complex|troponin | Troponin |
C0746730 | null | null | myocardial injury |
C0033384 | A mixed-function oxygenase that catalyzes the hydroxylation of a prolyl-glycyl containing peptide, usually in PROTOCOLLAGEN, to a hydroxyprolylglycyl-containing-peptide. The enzyme utilizes molecular OXYGEN with a concomitant oxidative decarboxylation of 2-oxoglutarate to SUCCINATE. The enzyme occurs as a tetramer of two alpha and two beta subunits. The beta subunit of procollagen-proline dioxygenase is identical to the enzyme PROTEIN DISULFIDE-ISOMERASES. | Protocollagen Prolyl Hydroxylase|Procollagen-proline,2-oxoglutarate 4-dioxygenase (substance)|Procollagen-Proline Dioxygenase|Dioxygenase, Procollagen-Proline|Procollagen-L-proline,2-oxoglutarate:oxygen oxidoreductase|Protocollagen Hydroxylase|proline hydroxylase|Prolyl-Glycyl-Peptide, 2-Oxoglutarate:Oxygen Oxidoreductase, 4-Hydroxylating|4-Hydroxylase, Procollagen Prolyl|Proline hydroxylase|Proline,2-oxoglutarate 4-dioxygenase|Collagen Proline Hydroxylase|Procollagen-proline,2-oxoglutarate 4-dioxygenase|Proline Protocollagen Hydroxylase|EC 1.14.11.2|P4H|Protocollagen Proline Hydroxylase|Prolylprotocollagen Hydroxylase|Prolyl Hydroxylase, Protocollagen|Prolyl 4-Hydroxylase, Procollagen|Proline, 2-Oxoglutarate Dioxygenase|Prolyl 4-Hydroxylase|Prolyl Hydroxylase|Protocollagen hydroxylase|Peptidyl Proline Hydroxylase|Hydroxylase, Collagen Proline|Proline Hydroxylase|Procollagen Prolyl 4-Hydroxylase|Prolylprotocollagen Dioxygenase|Hydroxylase, Protocollagen Prolyl|Protocollagen Proline 4-Hydroxylase|Proline,2-Oxoglutarate 4-Dioxygenase|Procollagen Proline Dioxygenase|Protocollagen Proline Dioxygenase|Procollagen Prolyl 4 Hydroxylase|Procollagen-Proline 4-Dioxygenase | Procollagen-Proline Dioxygenase |
C1568534 | null | null | lipid II |
C0042313 | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. | Vancomycine|Vancomycin-containing product|Product containing vancomycin (medicinal product)|vancomycin|VANCO|(2.2Sp,3.5Sa,2.6Sp)-O4.2,C3.4:C5.4,O4.6:C3.5,C2.7-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]|Vancomycin|(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid|Vancomycinum|Vancomycin (substance)|VANCOMYCIN|Vancomicina | vancomycin |
C0072972 | null | RAMOPLANIN|Ramoplanin|Ramoplanin (substance)|2-(((3alpha,5beta)-3-hydroxy-7,24-dioxocholan-24-yl)amino)-, (SP-4-2)- | ramoplanin |
C0085272 | A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. | Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-|leuprolide|Leuprorelina|LEUP|6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)|Leuprorelinum|Product containing leuprorelin (medicinal product)|6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig)|Leuproreline|Leuprorelin|Leuprolide|Leuprorelin-containing product|Leuprorelin (substance)|LEUPROLIDE|leuprorelin | leuprolide |
C0085272 | A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. | Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-|leuprolide|Leuprorelina|LEUP|6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)|Leuprorelinum|Product containing leuprorelin (medicinal product)|6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig)|Leuproreline|Leuprorelin|Leuprolide|Leuprorelin-containing product|Leuprorelin (substance)|LEUPROLIDE|leuprorelin | leuprolide |
C0011335 | Diagnostic tests conducted in order to measure the increment of active DENTAL CARIES over a period of time. | null | Dental Caries Activity Tests |
C1325592 | A multi-component enzymatic machine at the replication fork which mediates DNA replication. Includes DNA primase, one or more DNA polymerases, DNA helicases, and other proteins. [GOC:mah, GOC:vw] | null | replisome |
C0005290 | A family of globular proteins that form dimers with alpha tubulins. The alpha-beta tubulin dimers polymerize in a guanosine triphosphate (GTP)-dependent fashion to form microtubules. | Beta tubulin|beta Tubulin|beta-tubulin|Beta-tubulin|Tubulin Beta|beta tubulin|Beta Tubulin|Beta-Tubulin|beta-Tubulin|Beta tubulin (substance) | beta-Tubulin |
C0005290 | A family of globular proteins that form dimers with alpha tubulins. The alpha-beta tubulin dimers polymerize in a guanosine triphosphate (GTP)-dependent fashion to form microtubules. | Beta tubulin|beta Tubulin|beta-tubulin|Beta-tubulin|Tubulin Beta|beta tubulin|Beta Tubulin|Beta-Tubulin|beta-Tubulin|Beta tubulin (substance) | beta-Tubulin |
C1513486 | The type of ubiquitin modification determines the functional consequences for the modified protein. Monoubiquitination does not serve as a proteasome targeting signal, but plays other distinct roles. Target proteins are monoubiquitinated on one or more lysine residues, which serve as a signal for intracellular sorting as well as endocytosis of cell-surface proteins. Monoubiquitination of cell-surface receptors serves as a signal to target them to lysosome, where they are degraded by lysosomal proteases. (From PMID and NCI) | null | Monoubiquitination |
C0030940 | Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. | Proteinase|Proteolytic enzyme|peptide hydrolases|Proteases|peptide hydrolase|Proteolytic Enzymes|peptidases|Proteinases|PROTEOLYTIC ENZYME|Protease|Peptide Hydrolase|proteolytic enzymes|Peptidases|enzymes proteolytic|proteolytic|Substance with peptide hydrolase mechanism of action (substance)|Peptidase|Proteolytic Enzyme|Proteolytic enzymes|Peptide hydrolase|Esteroproteases|Substance with peptide hydrolase mechanism of action|Peptide Hydrolases|proteolytic enzyme|peptidase | Peptide Hydrolases |
C0814002 | Generation of cells within the nervous system. [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid, GOC:mtg_15jun06] | nervous system cell generation|Neurogeneses|Neural Development|Neurogenesis|neurogenesis|Neuronal Growth|neural development|Neural Growth | Neurogenesis |
C0010531 | A group of enzymes that are dependent on CYCLIC AMP and catalyze the phosphorylation of SERINE or THREONINE residues on proteins. Included under this category are two cyclic-AMP-dependent protein kinase subtypes, each of which is defined by its subunit composition. | Cyclic AMP-Dependent Protein Kinases|cyclic AMP dependent protein kinase|Cyclic AMP Dependent Protein Kinases|Protein Kinase, cAMP-Dependent|Cyclic AMP-Dependent Protein Kinase|cAMP-Dependent Protein Kinase|PKA|Adenosine Cyclic Monophosphate Dependent Protein Kinases|cAMP Dependent Protein Kinases|protein kinase A|Cyclic AMP Dependent Protein Kinase|cAMP-Dependent Protein Kinases|cyclic amp-dependent protein kinases|Adenosine Cyclic Monophosphate-Dependent Protein Kinases|Protein Kinase A|cAMP Protein Kinase|Protein Kinases, cAMP-Dependent|cAMP Dependent Protein Kinase|Protein Kinase, cAMP | Cyclic AMP-Dependent Protein Kinases |
C0872341 | A small, membranous protrusion from a dendrite that forms a postsynaptic compartment - typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable including thin", "stubby", "mushroom", and "branched", with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity." [GOC:nln] | Dendritic Spine|Spine, Dendritic|dendrite spine|Dendritic spine|dendritic spine|dendrites spines|Spines, Dendritic|Dendritic spine apparatus (cell structure)|dendritic spines|Dendritic spine apparatus | Dendritic Spines |
C0035804 | A mammalian order which consists of 29 families and many genera. | rodent|Rodent, NOS|Rodentia|Order Rodentia (organism)|rodentia|Rodents|Rodentias|ORDER RODENTIA - RODENTS OR GNAWING ANIMALS|rodents|Mammals, Rodents|Rodent|Order Rodentia | Rodent |
C0278252 | null | Poor prognosis|Prognosis poor|poor prognosis|Prognosis bad (finding)|prognosis poor | Prognosis bad |
C0041366 | Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. | Tumor Marker, Biologic|Marker, Biological Tumor|Markers, Neoplasm Metabolite|Tumor Marker, Biochemical|Markers, Biologic Tumor|Tumor Biomarkers|Biologic Tumor Markers|Biologic Tumor Marker|Metabolite Marker, Tumor|Tumor Marker, Biological|Biochemical tumour marker|Tumor Metabolite Marker|Tumor Markers, Biochemical|Tumor Markers, Biologic|Marker, Neoplasm Metabolite|Tumor Markers, Biological|Neoplasm Metabolite Marker|Carcinogen Markers|Biochemical tumor marker|Biochemical Tumor Marker|Markers, Tumor Metabolite|Biological Tumor Markers|Marker, Tumor Metabolite|Biochemical tumor marker (substance)|Metabolite Markers, Neoplasm|Marker, Biologic Tumor|Metabolite Markers, Tumor|Markers, Biological Tumor|Neoplasm Metabolite Markers|Metabolite Marker, Neoplasm|Biochemical Tumor Markers|biological tumor markers|Biological Tumor Marker|Markers, Biochemical Tumor|Markers, Carcinogen|Marker, Biochemical Tumor|Tumor Metabolite Markers | Biomarkers, Tumor |
C0035711 | The small RNA molecules, 73-80 nucleotides long, that function during translation (TRANSLATION, GENETIC) to align AMINO ACIDS at the RIBOSOMES in a sequence determined by the mRNA (RNA, MESSENGER). There are about 30 different transfer RNAs. Each recognizes a specific CODON set on the mRNA through its own ANTICODON and as aminoacyl tRNAs (RNA, TRANSFER, AMINO ACYL), each carries a specific amino acid to the ribosome to add to the elongating peptide chains. | trna|transfer RNA|transfer rna|transfer ribonucleic acid|RNA, transfer (tRNA)|RNA, Transfer|Ribonucleic acids, transfer|tRNA|Transfer RNA|Triplet Codon-Amino Acid Adaptor|transfer RNA (tRNA)|Transfer ribonucleic acid (substance)|Transfer ribonucleic acid | Transfer RNA |
C0451641 | Formation of stones in any part of the URINARY TRACT, usually in the KIDNEY; URINARY BLADDER; or the URETER. | urolithiasis|Urolithiasis, NOS|Lithiasis, Urinary|Urolithiasis (disorder)|Urinary Lithiasis|Urinary Stones|UROLITHIASIS|Urolithiasis | Urolithiasis |
C0006736 | An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones. | Calculus|CALCULI|calculus|Concretion, NOS|Calculi|calculi|body stone|Stone, NOS|Calculus (morphologic abnormality)|Single calculus|Stone|Concretion|Biliary or Urinary Stones|Single calculus (morphologic abnormality)|Stone - body material|Stone - body material (substance)|CALCULUS|Calculus, NOS | Calculi |
C0014609 | The layers of EPITHELIAL CELLS which cover the inner and outer surfaces of the cutaneous, mucus, and serous tissues and glands of the body. | Tissue, Epithelial|epithelial tissues|Epithelium|Epithelial tissue, NOS|Epithelial tissue|Portion of epithelium|Tissues, Epithelial|Epithelium (body structure)|epithelium|Epithelium, NOS|Textus epithelialis|epithelial tissue|Epithelial Tissues|Epithelial Tissue | Epithelium |
C0425422 | restriction of the amount of selected dietary constituent(s). | diets restricted|restrict diet|restricted diet|dietary restrictions|dietary restriction | restricted diet |
C0020500 | Excretion of an excessive amount of OXALATES in the urine. | Hyperoxaluria|oxaluria|hyperoxaluria|Hyperoxaluria (disorder)|Increased level of oxalate in urine|High urine oxalate levels|Oxaluria | Hyperoxaluria |
C1156902 | The chemical reactions and pathways resulting in the formation of heparin, any member of a group of glycosaminoglycans of average Mr (6000-20000), consisting predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. [GOC:mah, ISBN:0198506732] | heparin anabolism|heparin biosynthesis|heparin formation|heparin synthesis | heparin biosynthetic process |
C0019143 | A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS. | Heparan sulfate|heparan sulfate|heparan sulphate|Sulfate, Heparitin|Heparan sulphate|Heparan sulfate (substance)|Heparitin, sulfate|Heparan Sulfate|Heparitin sulfate|Sulfate, Heparan | Heparitin Sulfate |
C0020817 | Component of dermatan sulfate. Differs in configuration from glucuronic acid only at the C-5 position. | Iduronic acid|Acid, Iduronic | Iduronic Acid |
C0058984 | A component of eukaryotic initiation factor 4F that as an RNA helicase involved in unwinding the secondary structure of the 5' UNTRANSLATED REGION of MRNA. The unwinding facilitates the binding of the 40S ribosomal subunit. | Eukaryotic Peptide Initiation Factor 4A|Peptide Initiation Factor EIF 4A|Eukaryotic Initiation Factor EIF 4A|Eukaryotic Initiation Factor 4A|Peptide Initiation Factor EIF-4A|Eukaryotic Peptide Initiation Factor-4A|Initiation Factor-4A, Eukaryotic|EIF-4A|Eukaryotic Initiation Factor-4A|Eukaryotic Initiation Factor EIF-4A | Eukaryotic Initiation Factor-4A |
C0038951 | A document used in a method of data collection that involves interviewing (or giving questionnaires to) a representative and often large group of people. | Survey Instrument|Surveys|questionnaire or interview|Survey|survey instrument|survey | Surveys |
C0677908 | Treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time. | Maintenance Therapy|Maintenance therapy (procedure)|maintenance therapy | Maintenance therapy |
C0200635 | The number of LYMPHOCYTES per unit volume of BLOOD. | Total lymphocyte count|Lymphocyte Counts, Total|count lymphocytes total|Lymphocyte Counts|Lymphocytes|Lymphocyte Numbers|LYM|Total Lymphocyte Count|lymphocyte count|total lymphocyte count|lymphocyte number|Lymphocyte count|Total lymphocyte count (procedure)|Lymphocyte Number|lymphocyte counts|Lymphocyte Count, Total|count lymphocytes|counts lymphocyte|Lymphocyte Count|Total Lymphocyte Counts|Lymphocyte count (procedure) | Lymphocyte Count measurement |
C0334634 | A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1). | Mantle-Cell Lymphoma|Mantle-Zone Lymphoma|Lymphomas, Mantle-Zone|Lymphoma, Mantle Cell|Lymphoma, Centrocytic Small Cell|Mantle Cell Lymphoma|Lymphomas, Centrocytic Small-Cell|Lymphoma, Mantle-Zone|Lymphocytic lymphosarcoma, intermediate differentiation|Lymphocytic lymphosarcoma, intermediate differentiation, diffuse|Lymphoma, Mantle-Cell|Mantle-Cell Lymphomas|Lymphocytic lymphoma, poorly differentiated, diffuse|Centrocytic Small-Cell Lymphoma|Malignant lymphoma, lymphocytic, poorly differentiated, diffuse|Lymphomas, Mantle-Cell|Small-Cell Lymphomas, Centrocytic|Diffuse Lymphocytic Lymphoma, Poorly Differentiated|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|diffuse PDL lymphoma|DPDL lymphoma|Lymphoma, Small-Cell, Centrocytic|Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated|Mantle Zone Lymphoma|Mantle cell lymphoma|Diffuse Lymphocytic Lymphoma, Poorly-Differentiated|Mantle zone lymphoma|Mantle-Zone Lymphomas|Mantle cell lymphoma (morphologic abnormality)|Small-Cell Lymphoma, Centrocytic|Lymphoma, Centrocytic Small-Cell|Lymphocytic Lymphoma, Diffuse, Poorly Differentiated|diffuse poorly-differentiated lymphocytic lymphoma|Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated|Centrocytic Small-Cell Lymphomas|Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse |
C0909381 | A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor. | Valganciclovir|Ganciclovir L valyl Ester|L-Valine, 2-((2-amino-3,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester|Valganciclovir-containing product|L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl Ester|valganciclovir|Ganciclovir L-valyl Ester|VGCV|VALGANCICLOVIR|Valganciclovir (substance)|valGANciclovir|Product containing valganciclovir (medicinal product) | valganciclovir |
C0909381 | A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor. | Valganciclovir|Ganciclovir L valyl Ester|L-Valine, 2-((2-amino-3,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester|Valganciclovir-containing product|L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl Ester|valganciclovir|Ganciclovir L-valyl Ester|VGCV|VALGANCICLOVIR|Valganciclovir (substance)|valGANciclovir|Product containing valganciclovir (medicinal product) | valganciclovir |
C0010823 | Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. | Cytomegalic Inclusion Diseases|Cytomegaloviral Infection|Infections, Cytomegalovirus|Cytomegalovirus Infections|Inclusion Disease, Cytomegalic|Cytomegalic Inclusion Disease|cmv infection|Cytomegalovirus infections|Cytomegalovirus infection, NOS|Cytomegaloviral disease|Salivary Gland Virus Disease|CMV Infections|cmv cytomegalovirus infection|CMV INFECTION|Cytomegalic inclusion disease|Disease due to Cytomegalovirus|Inclusion Disease|inclusion disease|CMV Infection|Cytomegalovirus infection (disorder)|Inclusion Diseases, Cytomegalic|CMV|Cytomegalovirus disease|CYTOMEGALIC INCLUSION DISEASE|Cytomegalovirus infection|CMV - Cytomegalovirus infection|cytomegaloviral infection|Infection, Cytomegalovirus|CMV infection|Cytomegalovirus Infection|HCMV Infection|cytomegalovirus infection|cytomegalovirus infections|CYTOMEGALOVIRUS INFECTION|Disease, Cytomegalic Inclusion|Diseases, Cytomegalic Inclusion|Inclusion Diseases|Salivary gland virus disease|cytomegaloviral disease|cytomegaloviral infections|cmv infections|cytomegalic inclusion disease | Cytomegalovirus Infections |
C0017066 | An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Ganciclovirum|9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine|DHPG|2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone|2'NDG|2'-Nor-2'-deoxyguanosine|2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one|Ganciclovir (substance)|Ganciclovir-containing product|2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one|Gancyclovir|Product containing ganciclovir (medicinal product)|2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol|ganciclovir|2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one|9-[(1,3-dihydroxy-2-propoxy)methyl]guanine|2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one|2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol|Ganciclovir|dihydroxypropoxymethylguanine|9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine|GANCICLOVIR|Nordeoxyguanosine|GCV|GA2|gancyclovir|6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- | ganciclovir |
C1456094 | null | Allogeneic hematopoietic stem cell transplant with purging|Allogeneic hematopoietic stem cell transplant|Allogeneic hematopoietic stem cell transplant with cell depletion | allogeneic hematopoietic stem cell transplant with purging |
C0025241 | An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. | melfalan|p-di(chloroethyl)amino-L-phenylalanine|L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine|L-Phenylalanine mustard|Phenylalanine mustard|Melphalan-containing product|4-(Bis(2-chloroethyl)amino)phenylalanine|3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine|L-Sarcolysine|L-Sarcolysin Phenylalanine mustard|L-Phenylalanine Mustard|L-Sarcolysin|p-N-Bis(2-chloroethyl)amino-L-phenylalanine|L-PAM|4-(Bis(2-chloroethyl)amino)-L-phenylalanine|L-phenylalanine mustard|melphalan|Melphalan|4-[bis(2-chloroethyl)amino]-L-phenylalanine|MELPHALAN|p-N,N-bis(2-chloroethyl)amino-L-phenylalanine|p-Di-(2-chloroethyl)amino-L-phenylalanine|Product containing melphalan (medicinal product)|Melphalan (substance)|phenylalanine mustard|3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine|p-Bis(beta-chloroethyl)aminophenylalanine|alanine nitrogen mustard|L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-|p-L-Sarcolysin|phenylalanine nitrogen mustard|L-sarcolysin|Alanine Nitrogen Mustard|Phenylalanine Nitrogen Mustard|L-sarcolysine|Melfalano|Mustard, Phenylalanine|Phenylalanine nitrogen mustard|l-pam|Phenylalanine Mustard|L-sarcolysin phenylalanine mustard|l-phenylalanine mustard | melphalan |
C0037369 | Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. | smoking|smokings|smokes|Smoking|SMOKING | Smoking |
C0018957 | The blood-making organs and tissues, principally the bone marrow and lymph nodes. | Hematopoietic system|Hematopoietic Systems|Hematopoietic system structure (body structure)|Haematopoietic system structure|Organa haemopoietica|haematopoietic|haematopoietic system|Hematopoietic Body System|Hematologic Organ System|Haematopoietic system, NOS|Haematopoietic system|Haematopoietic|hematopoietic system|Hematopoietic system, NOS|hemopoietic system|System, Hematopoietic|Hemopoietic system|Organ System, Hematologic|Hematologic Body System|Body System, Hematologic|Hematopoietic system structure|Hematopoietic System | Hematopoietic System |
C0242602 | Transplantation of PERIPHERAL BLOOD STEM CELLS. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW. | Transfusion of stem cells|peripheral stem cell transplantation|Second stage peripheral stem cell infusion|Peripheral Stem Cell Transplant|peripheral blood progenitor cell transplantation|PBSCT|peripheral stem cell support|PBSC transplantation|PBSC - Peripheral blood stem cell graft|Peripheral blood stem cell transplantation|Stem Cell Transplantation, Peripheral|Peripheral blood stem cell graft|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cell graft (procedure)|Transplantation, Peripheral Stem Cell|PBPC transplantation|Peripheral Stem Cell Support|Peripheral Stem Cell Transplantation|transplantation, peripheral blood stem cell|Peripheral Blood Progenitor Cell Transplantation|Peripheral blood stem cell rescue|peripheral blood stem cell transplantation | Peripheral Stem Cell Transplantation |
C0024305 | Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. | Non-Hodgkin's Lymphoma|non hodgkin's lymphoma|NONHODGKINS LYMPHOMA|non-Hodgkin lymphoma|nonhodgkins lymphoma|Malignant lymphoma, diffuse, small cleaved cell|NHL - Non-Hodgkin's lymphoma|Malignant lymphoma, non-Hodgkin's|Non-Hodgkin`s lymphoma|Malignant lymphoma, small cleaved cell, diffuse|nonhodgkin lymphoma|nonHodgkin's lymphoma|Non Hodgkin Lymphoma|Malignant lymphoma, non-Hodgkin|MALIGNANT LYMPHOMA NON HODGKINS TYPE|Malignant lymphoma, non-Hodgkin's type|NON-HODGKIN LYMPHOMA|Nonhodgkin's Lymphoma|NHL|Non-Hodgkins lymphoma|LYMPHOMA, NON HODGKIN|Non-Hodgkin's Lymphoma (NHL)|Non-Hodgkin lymphoma, NOS|Non-Hodgkins Lymphoma|Non-Hodgkin lymphoma - category (morphologic abnormality)|Non-Hodgkin's lymphoma - disorder|Lymphoma, Non Hodgkin's|Lymphoma, Atypical Diffuse Small Lymphoid|Non-Hodgkin's lymphoma|lymphoma, non-Hodgkin's|Non-Hodgkin's lymphoma, NOS|Non-Hodgkin lymphoma - category|Non-Hodgkin's lymphoma (clinical)|Non-Hodgkin lymphoma (category)|non-hodgkin lymphoma|NON HODGKINS LYMPHOMA|Lymphoma, Nonhodgkin's|Lymphoma, Non-Hodgkins|Lymphoma, Small Cleaved-Cell, Diffuse|non hodgkins lymphoma|nhl|non-hodgkins lymphoma|non hodgkin's lymphoma (NHL)|Lymphoma, Nonhodgkins|Lymphoma, Non Hodgkins|non-hodgkin's lymphoma|Non Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin|Lymphoma, Non Hodgkin|Diffuse Small Cleaved Cell Lymphoma|Nonhodgkins Lymphoma|Non-Hodgkin lymphoma, no ICD-O subtype|non hodgkin lymphoma|Small Cleaved-Cell Lymphoma, Diffuse|Non-Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype|Diffuse Small Cleaved-Cell Lymphoma|Lymphoma, Nonhodgkin|Small Cleaved Cell Lymphoma, Diffuse|Diffuse non-Hodgkin's small cleaved cell (diffuse) lymphoma|Malignant lymphoma, non-Hodgkin's, NOS|Non-Hodgkin lymphoma|NHL, NOS|Non-Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Non-Hodgkin's lymphoma (disorder)|Lymphoma, Small Cleaved Cell, Diffuse|Non-Hodgkin Lymphoma|Lymphoma, Non-Hodgkin's|nonhodgkin's lymphoma | Lymphoma, Non-Hodgkin |
C0021753 | An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane. | Interleukin 1 beta|interleukin 1 beta|Interleukin-1beta|Interleukin-1 beta (substance)|interleukin-1 beta|il-1 beta|interleukin 1beta|IL-1beta|IL-1 beta|Interleukin 1beta|interleukin-1, beta|Catabolin|Interleukin-1 beta|beta interleukin-1|interleukin-1beta | interleukin-1, beta |
C0162371 | Blood from the umbilical cord of a newborn baby. This blood contains high concentrations of stem cells (cells from which all blood cells develop). | Blood, Cord|Blood, Umbilical Cord|Cord blood|umbilical cord blood|Umbilical Cord Blood|cord blood|Blood, cord|Unmanipulated Cord Blood|Cord Bloods|CORD BLOOD|Bloods, Cord|Cord blood (substance)|Umbilical Cord Bloods|Cord Blood|Bloods, Umbilical Cord|Cord Blood, Umbilical|Cord Bloods, Umbilical | Umbilical Cord Blood |
C0021755 | A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. | interleukin-1|IL1|Macrophage Cell Factor|T Helper Factor|Interleukin I|Epidermal Cell Derived Thymocyte-Activating Factor|il 1|LAF|il-1|il1|Lymphocyte activating factor|Lymphocyte-Stimulating Hormone|Interleukin-1 (substance)|IL-1|LAF (lymphocyte activating factor)|Interleukin-1|Epidermal Cell Derived Thymocyte Activating Factor|Lymphocyte Activating Factor|Interleukin 1|interleukin 1|Lymphocyte-Activating Factor|IL1B|lymphocyte activating factor|interleukin-1 (IL-1) | Interleukin-1 |
C0034392 | A flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. | Dikvertin|3,3',4',5,7-pentahydroxyflavone|Quercetin (substance)|Quercetin|Quercetin-containing product|2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|quercetin|Sophoretin|3,5,7,3',4'-Pentahydroxyflavone|3,3',4',5,7-Pentahydroxyflavone|C.I. Natural Yellow 10|C.I. natural yellow 10|4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-|Product containing quercetin (medicinal product)|QUERCETIN | quercetin |
C0431085 | null | tumor cell|Tumour cell|Tumor cell (cell)|Tumor cell|tumour cell|Tumour cells|Tumor cells, uncertain whether benign or malignant (morphologic abnormality)|Tumour cells, uncertain whether benign or malignant|Tumor cells, NOS|Tumor cells|tumor cells|Tumour cells, NOS|Tumor cells, uncertain whether benign or malignant|tumour cells | Tumor cells, uncertain whether benign or malignant |
C0758661 | null | Mycobacterium SA-5K | SA-5K protein, Mycobacterium |
C0758661 | null | Mycobacterium SA-5K | SA-5K protein, Mycobacterium |
C0596290 | All of the processes involved in increasing CELL NUMBER including CELL DIVISION. | Number Growth, Cell|Cell Proliferation Process|Cell Number Growth|Cell Multiplication|Cellular Proliferation|Multiplication, Cell|Cell proliferation|Growth, Cell Number|Proliferation, Cellular|cell proliferation|Cell Proliferation|Cell Growth in Number|Proliferation, Cell | Cell Proliferation |
C0006790 | A 17-alkylated orally active androgenic steroid. Calusterone may alter the metabolism of estradiol and reduce estrogen production. (NCI04) | 7-.beta.-17-.alpha.-dimethyltestosterone|7-beta,17-alpha-Dimethyl testosterone|17beta-Hydroxy-7beta,17alpha-dimethylandrost-4-ene-3-one|androst-4-en-3-one, 7.beta., 17.alpha.-dimethyl-17.beta.-hydroxy-|calusterone|17-beta-hydroxy-7-beta, 17-dimethylandrost-4-ene-3-one|Androst-4-en-3-one, 7.beta., 17.alpha.-dimethyl-17.beta.-hydroxy-|7-beta,17-Dimethyltestosterone|Androst-4-en-3-one, 7beta, 17alpha-dimethyl-17beta-hydroxy-|Calusterone|Calusteronum|17 Beta-OH-7 beta, 17 alpha-dimethyl-androst-4-ene-3-one|Androst-4-en-3-one, 17beta-hydroxy-7beta,17-dimethyl- (8CI)|Dimethyltestosterone|Androst-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7beta,17beta)- (9CI)|Androst-4-en-3-one, 17.beta.-hydroxy-7.beta.,17-dimethyl- (8CI)|7 Beta, 17 Alpha-dimethyltestosterone|7 beta, 17 alpha-dimethyltestosterone|7 beta,17 alpha-dimethyltestosterone|CALUSTERONE|dimethyltestosterone|7beta,17alpha-Dimethyltestosterone|Calusterone (substance)|17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one|17-Beta-hydroxy-7-beta, 17-dimethylandrost-4-ene-3-one|7beta,17-Dimethyltestosterone|17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one|CLS|androst-4-en-3-one, 17.beta.-hydroxy-7.beta.,17-dimethyl- (8CI)|androst-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7.beta.17.beta.)- (9CI)|7.beta., 17.alpha.-Dimethyltestosterone|Calusterona|17 beta-OH-7 beta, 17 alpha-dimethyl-androst-4-ene-3-one|Androst-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7.beta., 17.beta.)- (9CI) | Calusterone |
C0009212 | A group of islands in the Indian Ocean, south of Indonesia and west of Christmas Island. | Cocos (Keeling) Islands|COCOS (KEELING) ISLANDS|CCK|CC | Cocos (Keeling) Islands |
C0752312 | A superfamily of PROTEIN-SERINE-THREONINE KINASES that are activated by diverse stimuli via protein kinase cascades. They are the final components of the cascades, activated by phosphorylation by MITOGEN-ACTIVATED PROTEIN KINASE KINASES, which in turn are activated by mitogen-activated protein kinase kinase kinases (MAP KINASE KINASE KINASES). | Mitogen-Activated Protein Kinase|Protein Kinases, Mitogen-Activated|Map Kinase|Mitogen Activated Protein Kinases|ERK|mapk|mitogen activated protein kinase (MAPK)|MAPK|map kinase|Mitogen-Activated Protein Kinases|MAP kinase|Extracellular Signal-Regulated Kinases|Kinases, Mitogen-Activated Protein|mitogen activated protein kinase|EC 2.7.2-|Mitogen-activated protein kinases | Mitogen-Activated Protein Kinases |
C0474808 | null | follicular neoplasm|follicular neoplasms|follicular tumors|Follicular neoplasm (morphologic abnormality)|Follicular tumour|follicular tumor|Follicular tumor | Follicular neoplasm |
C0073265 | null | null | ribosomal protein 49 |
C0073265 | null | null | ribosomal protein 49 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0051014 | null | AHR-10718|Urea, N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl)ethyl)-, (Z)-2-butenedioate | AHR 10718 |
C0024299 | A general term for various neoplastic diseases of the lymphoid tissue. | lymphoma (Hodgkin and non-Hodgkin)|Sarcoma, Germinoblastic|Lymphoma (Hodgkin's and Non-Hodgkin's)|Malignant lymphoma (disorder)|Lymphoma, Malignant|Malignant lymphoma - category|lymphomas malignant|Germinoblastomas|lymphoma malignant|Malignant Lymphomas|malignant lymphoma|Lymphomatous|lymphoma (Hodgkin's and non-Hodgkin's)|Malignant lymphoma, no ICD-O subtype|Malignant Lymphoma|Lymphomas, Malignant|Germinoblastic sarcoma|Lymphoma (Hodgkin and Non-Hodgkin)|lymphoma|Malignant lymphoma, NOS|Lymphoma NOS|Malignant lymphoma, no International Classification of Diseases for Oncology subtype|Malignant lymphoma NOS|Lymphosarcoma|LYMPHOMA, MALIGNANT|Malignant lymphoma|Malignant lymphoma - category (morphologic abnormality)|Sarcomas, Germinoblastic|Germinoblastic Sarcomas|LYMPHOMA MALIGNANT|malignant lymphomas|Lymphoma, NOS|Malignant lymphoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Cancer of lymphatic system|Lymphoma|LYMPHOMA|Reticulolymphosarcoma|Germinoblastoma|Lymphomas|Germinoblastic Sarcoma|lymphomas|Reticulolymphosarcomas | Lymphoma |
C1336776 | A transcription cofactor that activates transcription from a RNA polymerase II promoter but does not bind DNA itself. | Transcriptional Coactivator|Transcriptional Activator/Coactivator|Transcription Factor Coactivator|Transcription Activator|Transcriptional Activator | Transcription Coactivator |
C1336776 | A transcription cofactor that activates transcription from a RNA polymerase II promoter but does not bind DNA itself. | Transcriptional Coactivator|Transcriptional Activator/Coactivator|Transcription Factor Coactivator|Transcription Activator|Transcriptional Activator | Transcription Coactivator |
C1148673 | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). [GOC:dph, GOC:jl, GOC:tb, GOC:vw] | DNA binding|dna binding|DNA Binding Interaction | DNA Binding |
C0056695 | Ubiquitously or widely expressed human cAMP Responsive Element Binding Proteins (bZIP/CREB Family) are conserved nuclear bZIP domain dimeric transcription factors that bind to octameric DNA palindrome cAMP-response elements (CRE) present in many viral and cellular promoters and induce gene transcription in response to cAMP signaling pathways. CREB proteins bind to DNA as a homodimer or a heterodimer with JUN/c-Jun or ATF2/CREBP1. Increased cAMP levels following stimulation activate cAMP-dependent protein kinase A, which phosphorylates CREB proteins that stimulate transcription of cAMP-responsive genes. Calcium-regulated CREB transcription factors integrate calcium and cAMP signals. cAMP pathways provide a chief means by which cellular growth, differentiation, and function can be influenced by extracellular signals. (NCI) | Cyclic AMP-Responsive DNA-Binding Protein|CREB Protein|DNA Binding Protein, Cyclic AMP Responsive|Cyclic AMP Responsive DNA Binding Protein|DNA-Binding Protein, Cyclic AMP-Responsive|cAMP Response Element-Binding Protein|creb|Cyclic AMP Response Element-Binding Protein|cAMP Response Element Binding Protein|cyclic AMP response element binding protein (CREB)|CREB|CRE Binding Protein|cAMP Responsive Element Binding Protein|Cyclic AMP Responsive Element Binding Protein|cAMP response element binding protein|cyclic AMP-responsive DNA-binding protein | Cyclic AMP-Responsive DNA-Binding Protein |
C0056695 | Ubiquitously or widely expressed human cAMP Responsive Element Binding Proteins (bZIP/CREB Family) are conserved nuclear bZIP domain dimeric transcription factors that bind to octameric DNA palindrome cAMP-response elements (CRE) present in many viral and cellular promoters and induce gene transcription in response to cAMP signaling pathways. CREB proteins bind to DNA as a homodimer or a heterodimer with JUN/c-Jun or ATF2/CREBP1. Increased cAMP levels following stimulation activate cAMP-dependent protein kinase A, which phosphorylates CREB proteins that stimulate transcription of cAMP-responsive genes. Calcium-regulated CREB transcription factors integrate calcium and cAMP signals. cAMP pathways provide a chief means by which cellular growth, differentiation, and function can be influenced by extracellular signals. (NCI) | Cyclic AMP-Responsive DNA-Binding Protein|CREB Protein|DNA Binding Protein, Cyclic AMP Responsive|Cyclic AMP Responsive DNA Binding Protein|DNA-Binding Protein, Cyclic AMP-Responsive|cAMP Response Element-Binding Protein|creb|Cyclic AMP Response Element-Binding Protein|cAMP Response Element Binding Protein|cyclic AMP response element binding protein (CREB)|CREB|CRE Binding Protein|cAMP Responsive Element Binding Protein|Cyclic AMP Responsive Element Binding Protein|cAMP response element binding protein|cyclic AMP-responsive DNA-binding protein | Cyclic AMP-Responsive DNA-Binding Protein |
C0017255 | null | gene activation|Activation, Gene|Gene Activation | Gene Activation |
C0057820 | null | 2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido(4,3-b)indole|Dicarbine|carbidine|DICARBINE|2,3,4,4a,5,9b-Hexahydro-2,8-dimethyl-1H-pyrido(4,3-b)indole|1H-Pyrido(4,3-b)indole, 2,3,4,4a,5,9b-hexahydro-2,8-dimethyl- | dicarbine |
C0254123 | A membrane protein homologous to the ERM (Ezrin-Radixin-Moesin) family of cytoskeleton-associated proteins which regulate physical properties of membranes. Alterations in neurofibromin 2 are the cause of NEUROFIBROMATOSIS 2. | merlin|Merlin (substance)|Schwannomin Protein|Gene Product, NF2|NF2|Schwannomin|Merlin|Moesin-Ezrin-Radixin-Like Protein|Neurofibromin 2|Neurofibromatosis Type 2 Protein|Protein, Schwannomin|NF2 Gene Product|Schwannomerlin|Neurofibromatosis 2 Gene Product|Moesin Ezrin Radixin Like Protein|Neurofibromatosis type 2 protein|Moezin-ezrin-radixin-like protein | Neurofibromin 2 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.